OpenAccessBelV2, Main, Exploration, bibRecord, 000693

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

Identifieur interne : 000693 ( Main/Exploration ); précédent : 000692; suivant : 000694

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

Auteurs : John J. V. Mcmurray [Royaume-Uni] ; Milton Packer [États-Unis] ; Akshay S. Desai [États-Unis] ; Jim Gong [États-Unis] ; Martin P. Lefkowitz [États-Unis] ; Adel R. Rizkala [États-Unis] ; Jean Rouleau [Canada] ; Victor C. Shi [États-Unis] ; Scott D. Solomon [États-Unis] ; Karl Swedberg [Suède] ; Michael R. Zile [États-Unis]

Source :

European Journal of Heart Failure [ 1388-9842 ] ; 2013-09.

RBID : ISTEX:E4BCF3A412832D79167B147CF84A85AE73D01D6F

Abstract

Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone system (RAAS), potentially beneficial counter‐regulatory systems are also active in HF. These promote vasodilatation and natriuresis, inhibit abnormal growth, suppress the RAAS and sympathetic nervous system, and augment parasympathetic activity. The best understood of these mediators are the natriuretic peptides which are metabolized by the enzyme neprilysin. LCZ696 belongs to a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides.

Url:

https://api.istex.fr/document/E4BCF3A412832D79167B147CF84A85AE73D01D6F/fulltext/pdf

DOI: 10.1093/eurjhf/hft052

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001645
to stream Istex, to step Curation: 001598
to stream Istex, to step Checkpoint: 000350
to stream Main, to step Merge: 000694
to stream Main, to step Curation: 000693

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)</title>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
</author>
<author><name sortKey="Packer, Milton" sort="Packer, Milton" uniqKey="Packer M" first="Milton" last="Packer">Milton Packer</name>
</author>
<author><name sortKey="Desai, Akshay S" sort="Desai, Akshay S" uniqKey="Desai A" first="Akshay S." last="Desai">Akshay S. Desai</name>
</author>
<author><name sortKey="Gong, Jim" sort="Gong, Jim" uniqKey="Gong J" first="Jim" last="Gong">Jim Gong</name>
</author>
<author><name sortKey="Lefkowitz, Martin P" sort="Lefkowitz, Martin P" uniqKey="Lefkowitz M" first="Martin P." last="Lefkowitz">Martin P. Lefkowitz</name>
</author>
<author><name sortKey="Rizkala, Adel R" sort="Rizkala, Adel R" uniqKey="Rizkala A" first="Adel R." last="Rizkala">Adel R. Rizkala</name>
</author>
<author><name sortKey="Rouleau, Jean" sort="Rouleau, Jean" uniqKey="Rouleau J" first="Jean" last="Rouleau">Jean Rouleau</name>
</author>
<author><name sortKey="Shi, Victor C" sort="Shi, Victor C" uniqKey="Shi V" first="Victor C." last="Shi">Victor C. Shi</name>
</author>
<author><name sortKey="Solomon, Scott D" sort="Solomon, Scott D" uniqKey="Solomon S" first="Scott D." last="Solomon">Scott D. Solomon</name>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</author>
<author><name sortKey="Zile, Michael R" sort="Zile, Michael R" uniqKey="Zile M" first="Michael R." last="Zile">Michael R. Zile</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E4BCF3A412832D79167B147CF84A85AE73D01D6F</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1093/eurjhf/hft052</idno>
<idno type="url">https://api.istex.fr/document/E4BCF3A412832D79167B147CF84A85AE73D01D6F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001645</idno>
<idno type="wicri:Area/Istex/Curation">001598</idno>
<idno type="wicri:Area/Istex/Checkpoint">000350</idno>
<idno type="wicri:doubleKey">1388-9842:2013:Mcmurray J:dual:angiotensin:receptor</idno>
<idno type="wicri:Area/Main/Merge">000694</idno>
<idno type="wicri:Area/Main/Curation">000693</idno>
<idno type="wicri:Area/Main/Exploration">000693</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)</title>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>BHF Cardiovascular Research Centre, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Packer, Milton" sort="Packer, Milton" uniqKey="Packer M" first="Milton" last="Packer">Milton Packer</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas Southwestern Medical Center, TX, Dallas</wicri:regionArea>
<wicri:noRegion>Dallas</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Desai, Akshay S" sort="Desai, Akshay S" uniqKey="Desai A" first="Akshay S." last="Desai">Akshay S. Desai</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cardiovascular Medicine, Brigham and Women's Hospital, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gong, Jim" sort="Gong, Jim" uniqKey="Gong J" first="Jim" last="Gong">Jim Gong</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceutical Corporation, NJ, East Hanover</wicri:regionArea>
<wicri:noRegion>East Hanover</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lefkowitz, Martin P" sort="Lefkowitz, Martin P" uniqKey="Lefkowitz M" first="Martin P." last="Lefkowitz">Martin P. Lefkowitz</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceutical Corporation, NJ, East Hanover</wicri:regionArea>
<wicri:noRegion>East Hanover</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rizkala, Adel R" sort="Rizkala, Adel R" uniqKey="Rizkala A" first="Adel R." last="Rizkala">Adel R. Rizkala</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceutical Corporation, NJ, East Hanover</wicri:regionArea>
<wicri:noRegion>East Hanover</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rouleau, Jean" sort="Rouleau, Jean" uniqKey="Rouleau J" first="Jean" last="Rouleau">Jean Rouleau</name>
<affiliation wicri:level="3"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institut de Cardiologie, Université de Montréal, Montréal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Victor C" sort="Shi, Victor C" uniqKey="Shi V" first="Victor C." last="Shi">Victor C. Shi</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceutical Corporation, NJ, East Hanover</wicri:regionArea>
<wicri:noRegion>East Hanover</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Solomon, Scott D" sort="Solomon, Scott D" uniqKey="Solomon S" first="Scott D." last="Solomon">Scott D. Solomon</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cardiovascular Medicine, Brigham and Women's Hospital, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Cardiovascular Medicine Department, University of Gothenburg, Gothenburg</wicri:regionArea>
<wicri:noRegion>Gothenburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zile, Michael R" sort="Zile, Michael R" uniqKey="Zile M" first="Michael R." last="Zile">Michael R. Zile</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Medical University of South Carolina and RHJ Department of Veterans Administration Medical center, SC, Charleston</wicri:regionArea>
<wicri:noRegion>Charleston</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Heart Failure</title>
<title level="j" type="abbrev">European Journal of Heart Failure</title>
<idno type="ISSN">1388-9842</idno>
<idno type="eISSN">1879-0844</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-09">2013-09</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1062">1062</biblScope>
<biblScope unit="page" to="1073">1073</biblScope>
</imprint>
<idno type="ISSN">1388-9842</idno>
</series>
<idno type="istex">E4BCF3A412832D79167B147CF84A85AE73D01D6F</idno>
<idno type="DOI">10.1093/eurjhf/hft052</idno>
<idno type="ArticleID">EJHFHFT052</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1388-9842</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone system (RAAS), potentially beneficial counter‐regulatory systems are also active in HF. These promote vasodilatation and natriuresis, inhibit abnormal growth, suppress the RAAS and sympathetic nervous system, and augment parasympathetic activity. The best understood of these mediators are the natriuretic peptides which are metabolized by the enzyme neprilysin. LCZ696 belongs to a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
<li>Québec</li>
<li>Écosse</li>
</region>
<settlement><li>Glasgow</li>
<li>Montréal</li>
</settlement>
<orgName><li>Université de Glasgow</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Packer, Milton" sort="Packer, Milton" uniqKey="Packer M" first="Milton" last="Packer">Milton Packer</name>
</noRegion>
<name sortKey="Desai, Akshay S" sort="Desai, Akshay S" uniqKey="Desai A" first="Akshay S." last="Desai">Akshay S. Desai</name>
<name sortKey="Gong, Jim" sort="Gong, Jim" uniqKey="Gong J" first="Jim" last="Gong">Jim Gong</name>
<name sortKey="Lefkowitz, Martin P" sort="Lefkowitz, Martin P" uniqKey="Lefkowitz M" first="Martin P." last="Lefkowitz">Martin P. Lefkowitz</name>
<name sortKey="Rizkala, Adel R" sort="Rizkala, Adel R" uniqKey="Rizkala A" first="Adel R." last="Rizkala">Adel R. Rizkala</name>
<name sortKey="Shi, Victor C" sort="Shi, Victor C" uniqKey="Shi V" first="Victor C." last="Shi">Victor C. Shi</name>
<name sortKey="Solomon, Scott D" sort="Solomon, Scott D" uniqKey="Solomon S" first="Scott D." last="Solomon">Scott D. Solomon</name>
<name sortKey="Zile, Michael R" sort="Zile, Michael R" uniqKey="Zile M" first="Michael R." last="Zile">Michael R. Zile</name>
</country>
<country name="Canada"><region name="Québec"><name sortKey="Rouleau, Jean" sort="Rouleau, Jean" uniqKey="Rouleau J" first="Jean" last="Rouleau">Jean Rouleau</name>
</region>
</country>
<country name="Suède"><noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000693 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000693 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E4BCF3A412832D79167B147CF84A85AE73D01D6F
   |texte=   Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024